Stockscreener 앱 받기
40.95
2.80%
-1.18
시간 외 거래:
40.47
-0.48
-1.17%
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics sees its composite rating rise to 97 - MSN
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 14, 2026 - BioSpace
Travere Therapeutics TVTX Stock 2026 Outlook: Buy Rating Holds After FDA Approval of FILSPARI for FSGS - International Business Times Australia
Travere Therapeutics (TVTX) Shares Surge 33% in Trading - GuruFocus
TVTX (NASDAQ) Form 144 shows proposed resale after PRSU vesting, brokered by Morgan Stanley - Stock Titan
TVTX (NASDAQ: TVTX) files Form 144 to resell 7,215 RSU shares - Stock Titan
Elizabeth Reed reports sales of TVTX common stock (NASDAQ: TVTX) in Form 144 - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 lists RSU vesting and planned share sales - Stock Titan
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease - MedCity News
Travere’s Filspari approved for rare kidney disease FSGS - BioWorld News
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Travere Therapeutics (TVTX) Surges 32.5% in Market Performance - GuruFocus
Affiliate proposes sale of 9,052 TVTX shares via Morgan Stanley (TVTX) - Stock Titan
37,500-share planned sale at TVTX (NASDAQ: TVTX) — insider notice - Stock Titan
Travere Therapeutics Stock Skyrockets On Highly Anticipated FDA Approval - Investor's Business Daily
32,750-share Option Exercise Filed by TVTX (NASDAQ: TVTX) - Stock Titan
Stifel raises Travere Therapeutics price target on Filspari approval - Investing.com
Stifel raises Travere Therapeutics price target on Filspari approval By Investing.com - Investing.com Australia
Sandra Calvin insider sale reported (NASDAQ: TVTX) — 4,333 shares sold - Stock Titan
TVTX Maintained by Citigroup -- Price Target Raised to $53.00 - GuruFocus
Travere Therapeutics (TVTX) Sees 43% Surge After FDA Approval - GuruFocus
FDA approves Filspari for FSGS, Travere’s second indication By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 42.2 USD By Investing.com - Investing.com Australia
TVTX Maintains Rating by Wedbush -- Price Target Raised to $44 - GuruFocus
TVTX Maintained by Canaccord Genuity -- Price Target Raised to $56 - GuruFocus
TVTX Stock Jumps As FDA Approval Fuels Bullish Momentum - StocksToTrade
Ligand (LGND) Partners with Travere on FDA Approval for Filspari - GuruFocus
Travere wins long-awaited approval for kidney disease drug - BioPharma Dive
Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval - MEXC
TVTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $47 - GuruFocus
TVTX Stock Jumps As FILSPARI Wins Full FDA Approval - timothysykes.com
Travere Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
TVTX Maintained by Guggenheim -- Price Target Raised to $54.00 - GuruFocus
HC Wainwright Reiterates Buy Rating for Travere Therapeutics - National Today
Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday - Benzinga
Travere Therapeutics stock hits 52-week high at 42.2 USD - Investing.com
Travere Therapeutics Stock Soars 33% After FDA Approves FILSPARI as First Drug for Rare Kidney Disease FSGS - International Business Times Australia
Travere’s Filspari wins landmark US approval - The Pharma Letter
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Wedbush Raises Price Target on Travere Therapeutics to $44 From $39, Keeps Outperform Rating - marketscreener.com
Cantor Fitzgerald reiterates Travere stock rating on FSGS approval By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Stock Surges 44% After FDA Approves FILSPARI for Rare Kidney Disease - CoinCentral
Travere, Ligand win FDA label expansion for Filspari (TVTX) - Seeking Alpha
First approved FSGS drug gives Ligand a 9% sales royalty - Stock Titan
Travere Wins FDA Approval for FILSPARI in FSGS - TipRanks
FDA approves Travere Therapeutics’ Filspairi for expanded kidney disease use - Investing.com
FDA approves FILSPARI for FSGS in Travere (NASDAQ: TVTX) patients - Stock Titan
Travere Therapeutics Gets FDA Approval for Filspari - marketscreener.com
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS - BioSpace
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics (TVTX) Secures FDA Approval for FILSPARI - GuruFocus
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sp - The National Law Review
Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGSSlideshow (NASDAQ:TVTX) 2026-04-13 - Seeking Alpha
Travere Therapeutics Receives FDA Approval for New Drug - Intellectia AI
TVTX (NASDAQ: TVTX) Form 144 shows 65 RSU shares proposed for sale - Stock Titan
2.69%
0.25%
자본화:
|
볼륨(24시간):